{"title":"新冠病毒mRNA二次增强疫苗在台湾老年人中的免疫原性","authors":"Hao-Yuan Lee, Chih-Hsien Chuang, Chung-Guei Huang, Tzu-Chun Chuang, Yu-An Kung, Cheng-Hsun Chiu","doi":"10.1016/j.bj.2025.100834","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Limited research has explored the immunological effects of a second COVID-19 vaccine booster in older adults within Western Pacific countries.</p><p><strong>Methods: </strong>This study involved healthcare workers aged ≥65 years who received two doses of ChAdOx1 nCoV-19 (A), mRNA-1273 (M), or MVC-COV1901 (Mc), followed by a booster dose of mRNA-1273. Younger adults served as controls. Humoral and cellular immune responses were measured before and after the vaccination.</p><p><strong>Results: </strong>Younger adults exhibited the highest fold-rise in anti-spike IgG levels (13.20, p < 0.001), followed by the AAMM (9.93, p < 0.001), McMcMM (6.97), and MMMM (4.9, p < 0.05) groups. Cellular response increased most in the McMcMM group (3.77), followed by AAMM (3.04, p < 0.001), MMMM (2.24), and the younger group (1.08). Neutralizing activity against the D614G variant was highest in younger adults (7.77, p < 0.001), followed by AAMM (4.07, p < 0.001), MMMM (2.89, p < 0.05), and McMcMM (2.76). Against the XBB.1.16 variant, titers were significantly lower (17.33-29.08 times less than wild type). The highest fold-rise was observed in the McMcMM group (8.59), followed by AAMM (7.66, p < 0.001), MMMM (4.16), and younger adults (2.26).</p><p><strong>Conclusions: </strong>A second mRNA COVID-19 booster increased neutralizing antibodies and enhanced T cell responses against SARS-CoV-2 variants. Adapted vaccines targeting new subvariants are critical to strengthen immunity, particularly for older adults facing vaccine-resistant strains.</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100834"},"PeriodicalIF":4.1000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunogenicity of second booster-dose COVID-19 mRNA vaccine among older adults in Taiwan.\",\"authors\":\"Hao-Yuan Lee, Chih-Hsien Chuang, Chung-Guei Huang, Tzu-Chun Chuang, Yu-An Kung, Cheng-Hsun Chiu\",\"doi\":\"10.1016/j.bj.2025.100834\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Limited research has explored the immunological effects of a second COVID-19 vaccine booster in older adults within Western Pacific countries.</p><p><strong>Methods: </strong>This study involved healthcare workers aged ≥65 years who received two doses of ChAdOx1 nCoV-19 (A), mRNA-1273 (M), or MVC-COV1901 (Mc), followed by a booster dose of mRNA-1273. Younger adults served as controls. Humoral and cellular immune responses were measured before and after the vaccination.</p><p><strong>Results: </strong>Younger adults exhibited the highest fold-rise in anti-spike IgG levels (13.20, p < 0.001), followed by the AAMM (9.93, p < 0.001), McMcMM (6.97), and MMMM (4.9, p < 0.05) groups. Cellular response increased most in the McMcMM group (3.77), followed by AAMM (3.04, p < 0.001), MMMM (2.24), and the younger group (1.08). Neutralizing activity against the D614G variant was highest in younger adults (7.77, p < 0.001), followed by AAMM (4.07, p < 0.001), MMMM (2.89, p < 0.05), and McMcMM (2.76). Against the XBB.1.16 variant, titers were significantly lower (17.33-29.08 times less than wild type). The highest fold-rise was observed in the McMcMM group (8.59), followed by AAMM (7.66, p < 0.001), MMMM (4.16), and younger adults (2.26).</p><p><strong>Conclusions: </strong>A second mRNA COVID-19 booster increased neutralizing antibodies and enhanced T cell responses against SARS-CoV-2 variants. Adapted vaccines targeting new subvariants are critical to strengthen immunity, particularly for older adults facing vaccine-resistant strains.</p>\",\"PeriodicalId\":8934,\"journal\":{\"name\":\"Biomedical Journal\",\"volume\":\" \",\"pages\":\"100834\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.bj.2025.100834\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.bj.2025.100834","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：有限的研究探索了第二种COVID-19疫苗增强剂对西太平洋国家老年人的免疫影响。方法：本研究涉及年龄≥65岁的卫生保健工作者，他们接受了两剂ChAdOx1 nCoV-19 (A)、mRNA-1273 (M)或MVC-COV1901 (Mc)，随后接受了一剂mRNA-1273加强剂。年轻的成年人作为对照组。接种前后分别测定体液和细胞免疫应答。结果：青壮年组抗尖峰IgG水平上升幅度最大（13.20,p < 0.001），其次为AAMM组（9.93,p < 0.001）、McMcMM组（6.97）和MMMM组（4.9,p < 0.05）。细胞应答以McMcMM组增加最多（3.77），其次是AAMM组（3.04,p < 0.001）、MMMM组（2.24）和年轻组（1.08）。对D614G变异的中和活性在年轻人中最高（7.77,p < 0.001），其次是AAMM (4.07, p < 0.001), MMMM （2.89, p < 0.05）和McMcMM（2.76）。对XBB.1.16变异的滴度显著降低（比野生型低17.33-29.08倍）。McMcMM组的翻倍率最高（8.59），其次是AAMM （7.66, p < 0.001）、MMMM（4.16）和年轻人（2.26）。结论：第二种mRNA COVID-19增强剂增加了对SARS-CoV-2变体的中和抗体和增强的T细胞反应。针对新亚型的适应疫苗对于增强免疫力至关重要，特别是对于面临疫苗耐药菌株的老年人。
Immunogenicity of second booster-dose COVID-19 mRNA vaccine among older adults in Taiwan.
Background: Limited research has explored the immunological effects of a second COVID-19 vaccine booster in older adults within Western Pacific countries.
Methods: This study involved healthcare workers aged ≥65 years who received two doses of ChAdOx1 nCoV-19 (A), mRNA-1273 (M), or MVC-COV1901 (Mc), followed by a booster dose of mRNA-1273. Younger adults served as controls. Humoral and cellular immune responses were measured before and after the vaccination.
Results: Younger adults exhibited the highest fold-rise in anti-spike IgG levels (13.20, p < 0.001), followed by the AAMM (9.93, p < 0.001), McMcMM (6.97), and MMMM (4.9, p < 0.05) groups. Cellular response increased most in the McMcMM group (3.77), followed by AAMM (3.04, p < 0.001), MMMM (2.24), and the younger group (1.08). Neutralizing activity against the D614G variant was highest in younger adults (7.77, p < 0.001), followed by AAMM (4.07, p < 0.001), MMMM (2.89, p < 0.05), and McMcMM (2.76). Against the XBB.1.16 variant, titers were significantly lower (17.33-29.08 times less than wild type). The highest fold-rise was observed in the McMcMM group (8.59), followed by AAMM (7.66, p < 0.001), MMMM (4.16), and younger adults (2.26).
Conclusions: A second mRNA COVID-19 booster increased neutralizing antibodies and enhanced T cell responses against SARS-CoV-2 variants. Adapted vaccines targeting new subvariants are critical to strengthen immunity, particularly for older adults facing vaccine-resistant strains.
期刊介绍：
Biomedical Journal publishes 6 peer-reviewed issues per year in all fields of clinical and biomedical sciences for an internationally diverse authorship. Unlike most open access journals, which are free to readers but not authors, Biomedical Journal does not charge for subscription, submission, processing or publication of manuscripts, nor for color reproduction of photographs.
Clinical studies, accounts of clinical trials, biomarker studies, and characterization of human pathogens are within the scope of the journal, as well as basic studies in model species such as Escherichia coli, Caenorhabditis elegans, Drosophila melanogaster, and Mus musculus revealing the function of molecules, cells, and tissues relevant for human health. However, articles on other species can be published if they contribute to our understanding of basic mechanisms of biology.
A highly-cited international editorial board assures timely publication of manuscripts. Reviews on recent progress in biomedical sciences are commissioned by the editors.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
